Loading...
The role of radiation therapy for patients with pancreatic cancer remains controversial. Recent studies have indicated no survival benefit in locally unresectable disease from the use of radiation followed by chemotherapy versus chemotherapy alone. Also controversial is the contribution of the approved agent erlotinib for patients with metastatic disease.
Investigators now report the results of an international, randomized, open-label phase III trial involving 442 patients with locally advanced pancreatic cancer that addressed two questions: the contribution of erlotinib to chemotherapy and the role of radiotherapy in patients maintaining local disease after a period of induction chemotherapy.
Patients were treated with up-front chemotherapy …